REGISTER FOR SOSV’s VC-Founder Therapeutics Matchup July 13-17

Dahlia Biosciences

RNA analysis tools for research and diagnostic applications

Company details

Dahlia Biosciences is providing the next generation of multiplexed in situ single-cell RNA analysis tools for research and diagnostic applications. Our vision is to empower scientists to study and isolate cells at high resolution via sensitive, robust, and multiplexed RNA detection in both fixed and live cells.

The flow cytometry research market is estimated to be >$1.9 billion in 2020 growing 7%, of which approximately $1.3B is driven by annual reagents expenditures.

Dahlia Biosciences Quote Image
Un Kwon, CEO
Flow cytometry is a powerful technology to study complex cell populations, and is ubiquitous in the development of immuno-oncology and cell based therapies. We see a significant opportunity to scale single-cell RNA analysis to millions of cells by combining the throughput of flow cytometry with our CRISPR-based RNA detection reagents.

Get In Touch with Dahlia Biosciences

Please tell us a little bit about yourself and why you'd like to get connected. Dahlia Biosciences + SOSV will follow up with you via email.

This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.